Omnipod® for HCPs

𝗢𝗺𝗻𝗶𝗽𝗼𝗱® 𝟱’𝘀 𝗖𝘂𝘀𝘁𝗼𝗺 𝗙𝗼𝗼𝗱𝘀 𝗳𝗲𝗮𝘁𝘂𝗿𝗲 𝗶𝘀 𝗵𝗲𝗿𝗲! 𝗟𝗲𝗮𝗿𝗻 𝗳𝗿𝗼𝗺 𝗼𝘂𝗿 𝘀𝗽𝗼𝗻𝘀𝗼𝗿𝗲𝗱 𝗴𝘂𝗲𝘀𝘁 𝗗𝗿. Bajaj 𝗮𝗯𝗼𝘂𝘁 𝗵𝗼𝘄 𝘆𝗼𝘂 𝗰𝗮𝗻 𝘂𝘀𝗲 𝘁𝗵𝗶𝘀 𝗳𝗲𝗮𝘁𝘂𝗿𝗲 𝘁𝗼 𝘀𝗶𝗺𝗽𝗹𝗶𝗳𝘆 𝗯𝗼𝗹𝘂𝘀𝗶𝗻𝗴. Listen to the full podcast:  https://lnkd.in/g_9GU6Ch #Omnbipod5 #Omnipod 5 #diabetes #insulinpump #diabetesmanagement #diabetestechnology #diabetestech #medtech #healthtech #podcast #t1d #t2d

Omnipod® 5 provides personalized and adaptive insulin delivery using an algorithm that is built into the Pod. https://lnkd.in/ePCrmvid 1. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean time in range (70-180 mg/dL): ST vs. 13-week Omnipod 5: 45% vs. 66%, P<0.001. 2. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 in adults/adolescents and children = 64.7% vs. 73.9%; 52.5% vs. 68.0%. Study funded by Insulet 3. Sherr JL, et al. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (70-180mg/dL) in very young children (2 - 5.9 yrs) as measured by CGM: ST = 57.2%, 3-mo Omnipod 5 = 68.1%, P<0.05. Study funded by Insulet. Omnipod 5 is indicated for people with type 1 diabetes, ages 2 years and older and type 2 diabetes in persons 18 years of age and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Please see Omnipod.com/safety for important safety information. 

“Life Saving” Hear what Karen Lau, CDCES says about starting patients on Omnipod 5® “They can go about their own lives as normal as possible.” https://lnkd.in/egVndsjx.  #Omnipod 5

“What we’re seeing is tons of people that would just not even consider pumps, that are now saying ‘ok, I’m ready, I’m willing to try this.” https://lnkd.in/egVndsjx. Hear from Dr. Diana Isaacs, Endocrine Clinical Pharmacist, how Omnipod® 5’s automation and #tubeless design has “simplified care for so many people.” #Omnipod 5 Diana Isaacs, PharmD is an Endocrine Clinical Pharmacist. She has an ongoing commercial relationship with Insulet Corporation.

The Omnipod® 5 app for iPhone includes a Custom Foods feature designed to simplify carb entry for your patients’ favorite foods and meals. https://lnkd.in/ey4HwA53 #Diabetes #DiabetesManagement #DiabetesCare #DiabetesTech #MedTech #Omnipod5

Team Omnipod® is live at #APhA2025! Join us today through March 23rd at booth 617 for your dose of inspiration. Come learn more about dispensing affordable tubeless automated insulin pumps to your patients with type 1 and type 2 diabetes. Majority of Omnipod 5 users pay less than $30/month¹. Plus, did you know that Omnipod is available for all Medicare patients through their part D benefit? Unlike traditional insulin pumps through part B, there is no c-peptide requirement² for your patients with type 1 and type 2 diabetes to get Omnipod! American Pharmacists Association #pharmacists #APhA #DiabetesCare #type1diabetes #type2diabetes #forpharmacy #pharmacystudent Omnipod 5 is indicated for people with type 1 diabetes, ages 2 years and older and type 2 diabetes in persons 18 years of age and older. Rx only.  WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Please see Omnipod.com/safety for important safety information. 1. Majority defined as at least 50% of patient co-pays $30 or less per month. Among All Paid Omnipod 5 G7G6 Pods Commercial and Medicare Claims from January 2024 to December 2024. Includes benefits and offerings available through Insulet, such as the copay card program. Actual co-pay amount depends on patient’s health plan and coverage, they may fluctuate and be higher or lower than the advertised amount on a monthly basis. Source: IQVIA OPC Library 2. Based on Prior Authorization criteria established by Medicare part D plans with Omnipod on formulary and non-formulary Coverage Determination Form requirements

We’re excited that our latest publication SECURE-T2D study has also been published in Pharmacy Times! If you’ll be at #APhA2025 this week, visit us at booth 617 from March 21 to 23 to learn about dispensing the future of diabetes care for your patients with type 1 and type 2 diabetes with Omnipod® 5! Omnipod 5 is the only tubeless automated insulin delivery pump your patients can pick up at their local pharmacy with their insulin. American Pharmacists Association #pharmacists #APhA #DiabetesCare #type1diabetes #type2diabetes #forpharmacy #pharmacystudent Omnipod 5 is indicated for people with type 1 diabetes, ages 2 years and older and type 2 diabetes in persons 18 years of age and older. Rx only.  WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Please see Omnipod.com/safety for important safety information. 

Team Omnipod® is thrilled to be heading back to Nashville to “Ignite Inspiration” for #pharmacists at #APhA2025! Don’t miss the chance to be part of the game-changing revolution in automated insulin delivery and ensure your patients with type 1 and type 2 diabetes get the best diabetes care ever. If you’ll be at APhA, visit us at booth 617 to learn why Omnipod 5 is the #1 most requested insulin pump by patients¹ and join the 42,000+ pharmacies that have already dispensed Omnipod 5². @AmericanPharmacistsAssociation #APhA #DiabetesCare #type1diabetes #type2diabetes #forpharmacy #pharmacystudent Omnipod 5 is indicated for people with type 1 diabetes, ages 2 years and older and type 2 diabetes in persons 18 years of age and older. Rx only.  WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Please see Omnipod.com/safety for important safety information. 1. Omnipod was the pump most frequently requested by people with type 1 and type 2 diabetes in a survey with Endocrinologists conducted by dQ&A across the United States. n=77 (T1) and n=63 (T2); H2 2024; P.25. 2. Reflects total Omnipod 5 unique pharmacy dispensing count. Source: Insulet Data on File as of Q4 2024.

𝗧𝗵𝗲 𝗦𝗘𝗖𝗨𝗥𝗘-𝗧𝟮𝗗 𝘀𝘁𝘂𝗱𝘆 𝗶𝘀 𝗻𝗼𝘄 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗶𝗻 𝗝𝗔𝗠𝗔 𝗡𝗲𝘁𝘄𝗼𝗿𝗸 𝗢𝗽𝗲𝗻! The results show that Omnipod® 5 lowered A1C regardless of patients’ race, ethnicity, GLP-1 use, and whether they were carb counting or not. In patients with a baseline of A1C ≥9%, the A1C was lowered by 2.1% (-0.8% in full study population).¹ Learn more about #Omnipod 5 for type 2 diabetes. https://lnkd.in/eZu8YRpf #Diabetes #DiabetesManagement #DiabetesCare #DiabetesTech #MedTech #Research #Type2Diabetes #T2D #Omnipod5 1. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. 53 participants used carbohydrate counting pre-study with mean HbA1c: ST vs. 13-week Omnipod 5: 7.8% vs. 7.3%. 129 participants used fixed dose pre study with mean HbA1c: ST vs. 13-week Omnipod 5: 8.4% vs. 7.4%. 46 participants used sliding scale pre study with mean HbA1c: ST vs. 13-week Omnipod 5: 8.1% vs. 7.3%. 32 participants used set doses to bolus pre study with mean HbA1c: ST vs. 13-week Omnipod 5: 8.3% vs. 7.4%. 36 participants used other carb counting method pre study with mean HbA1c: ST vs. 13-week Omnipod 5: 8.5% vs. 7.4%, P=0.85. In a subgroup analysis of 164 participants who used GLP-1 RA mean HbA1c: baseline vs. 13-week Omnipod 5: 8.1% vs. 7.3%; compared to 132 participants who did not use GLP-1 RA mean HbA1c: baseline vs. 13-week Omnipod 5: 8.4% vs. 7.5% Interaction p-value p= 0.5

Insulin pumps aren’t just for patients with type 1 diabetes. The American Diabetes Association (ADA) recommends and recognizes multiple benefits from using insulin pumps, including automated insulin delivery systems (AIDs), for people with insulin-requiring type 2 diabetes. Learn what else the ADA now recommends in their 2025 Standards of Care. https://lnkd.in/eT_C7nHJ #ADAstandardsofcare #Diabetes #DiabetesManagement #DiabetesCare #DiabetesTech #MedTech #Research #Type2Diabetes #T2D